FLGT
Fulgent Genetics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
19.90
▼ 0.02 (0.10%)
MARKET · —
Price
Open
20.01
Prev close
19.92
Day high
20.03
Day low
19.57
Volume
309.44K
Market cap
$547.55M
P/E (TTM)
—
52W range
13.46 – 31.04
Trailing performance
Returnvs SPY
1W
+7.22%
+8.6%
1M
-0.40%
-4.1%
3M
+14.50%
+11.4%
6M
-14.15%
-25.2%
YTD
-24.25%
-36.5%
1Y
-6.92%
-26.9%
3Y
-41.56%
-115.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$547.55M
Enterprise value$294.49M
Revenue (TTM)$323.93M
Gross profit$115.26M
EBITDA$-89.46M
Net income$-84.38M
EPS (TTM)$-2.83
Free cash flow$-90.90M
Total cash$257.03M
Total debt$9.60M
Book value / share$36.40
Shares outstanding27.52M
Float16.69M
Short % of float14.97%
Dividend yield—
Beta (5Y)0.91
Valuation & profitability ratios
Trailing P/E—
Forward P/E-14.42
PEG ratio—
Price / sales—
Price / book0.55
EV / revenue0.91
EV / EBITDA-3.29
Gross margin35.58%
Operating margin-39.35%
Profit margin-26.05%
Return on equity-8.11%
Return on assets-6.30%
Debt / equity0.96
Current ratio6.34
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $322.67M | $283.47M | $289.21M | $618.97M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$60.51M | -$42.71M | -$167.82M | $143.40M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$60.51M | -$42.71M | -$167.82M | $143.40M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.44 | -0.58 | -32.2% |
| Mar 2026 | -0.35 | -0.36 | -3.4% |
| Dec 2025 | 0.03 | 0.16 | +436.4% |
| Sep 2025 | -0.22 | 0.14 | +162.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.65 | 1 | $86.30M | +2.7% |
| Next quarter | -0.69 | 1 | $88.90M | +6.7% |
| Current year | -2.27 | 1 | $331.70M | +2.8% |
| Next year | -1.38 | 1 | $382.70M | +15.4% |
Analyst targets & ownership
Mean target$19.00
High target$19.00
Low target$19.00
Implied upside-4.52%
Analyst count1
ConsensusNONE
Strong buy / Buy0 / 0
Hold1
Sell / Strong sell0 / 0
Held by insiders37.81%
Held by institutions59.29%
Institutions holding219
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+435.34K
Net buying
Buy transactions
7
441.32K shares
Sell transactions
4
5.98K shares
Net transactions
+11
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
10.40M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 2, 26 | GAO HANLIN Officer |
SELL | 1.69K | $30.19K | Direct |
| Jun 2, 26 | XIE JIAN President |
SELL | 2.15K | $38.38K | Direct |
| May 27, 26 | GAO HANLIN Officer |
SELL | 945 | $16.63K | Direct |
| May 27, 26 | XIE JIAN President |
SELL | 1.20K | $21.14K | Direct |
| May 14, 26 | GROVES REGINA E Director |
STOCK | 11.12K | $0 | Direct |
| May 14, 26 | NOHAILE MICHAEL Director |
STOCK | 5.56K | $0 | Direct |
| May 14, 26 | DONG LINDA Director |
STOCK | 11.12K | $0 | Direct |
| Feb 24, 26 | KIM PAUL Chief Financial Officer |
STOCK | 78.50K | $0 | Direct |
| Feb 24, 26 | GAO HANLIN Officer |
STOCK | 67.12K | $0 | Direct |
| Feb 24, 26 | HSIEH MING Chief Executive Officer |
STOCK | 187.44K | $0 | Direct |
| Feb 24, 26 | XIE JIAN President |
STOCK | 80.46K | $0 | Direct |
| Dec 2, 25 | GAO HANLIN Officer |
SELL | 1.07K | $30.46K | Direct |
| Dec 2, 25 | XIE JIAN President |
SELL | 1.14K | $32.30K | Direct |
| Nov 28, 25 | GAO HANLIN Officer |
SELL | 943 | $27.88K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
DONG LINDA |
Director | 38.76K | Stock Award(Grant) |
GAO HANLIN |
Officer | 990.37K | Sale |
GROVES REGINA E |
Director | 28.10K | Stock Award(Grant) |
HSIEH MING |
Chief Executive Officer | 9.04M | Stock Award(Grant) |
KIM PAUL |
Chief Financial Officer | 379.19K | Stock Award(Grant) |
MARSH LINDA |
Director | 27.64K | Stock Award(Grant) |
NOHAILE MICHAEL |
Director | 24.58K | Stock Award(Grant) |
XIE JIAN |
President | 588.42K | Sale |
Moving averages & technicals
SMA 10
19.08
+4.31% from price
SMA 20
18.94
+5.08% from price
SMA 50
19.42
+2.45% from price
SMA 100
17.93
+10.98% from price
SMA 200
21.05
-5.44% from price
EMA 12
19.20
+3.65% from price
EMA 26
19.19
+3.72% from price
EMA 50
19.06
+4.43% from price
RSI (14)
57.3
Neutral
MACD (12,26,9)
0.01
Hist 0.15
ATR (14)
0.66
3.30% of price
Realised vol 30D
68.6%
Annualised
Bollinger upper
20.61
20, 2σ
Bollinger lower
17.26
20, 2σ
50 / 200 cross
Death
19.42 vs 21.05
Trend bias
Below 200
-5.44%
Risk profile
Beta vs SPY
0.83
Less volatile than market
Correlation to SPY
0.18
Largely independent
Realised vol 30D
68.6%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-55.3%
Peak to trough
Max drawdown 5Y
-86.9%
Peak to trough
ATR 14
0.66
3.30% of price
Beta (reported)
0.91
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
1.68
Put-heavy session
Put / call open interest
3.96
Positioning, not flow
Max pain
17.50
-12.1% from spot
ATM implied vol
61.3%
Nearest strike to spot
Skew (10% OTM)
-7.4%
Calls bid over puts
Call volume
19
Contracts, this expiry
Put volume
32
Contracts, this expiry
Heaviest call OI
20.00
42 contracts
Heaviest put OI
17.50
217 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Fulgent Genetics (FLGT) Q2 2026 Earnings Call Transcript
Motley Fool · 15d ago
Fulgent Genetics (FLGT) Stock Gets Fair Value Boost After Analysts Raised Targets
Simply Wall St. · 16d ago
Fulgent Genetics, Inc. Q2 2026 Earnings Call Summary
Moby · 22d ago
Fulgent Genetics Inc (FLGT) (Q2 2026) Earnings Call Highlights: Strategic Progress Amid Revenue ...
GuruFocus.com · 22d ago
Fulgent Genetics Q2 Earnings Call Highlights
MarketBeat · 23d ago
Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Misses Revenue Estimates
Zacks · 23d ago
Fulgent Reports Second Quarter 2026 Financial Results
Business Wire · 23d ago
Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
Business Wire · 44d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.